Basilea push­es back FDA sub­mis­sion for an­tibi­ot­ic over CMO is­sues

Basilea Phar­ma­ceu­ti­ca said it’s en­coun­ter­ing a man­u­fac­tur­ing de­lay that will af­fect when the com­pa­ny is able to sub­mit its an­tibi­ot­ic cefto­bip­ro­le for FDA ap­proval. …

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER